|

Dual-target CAR-NK cells Clinical Trials

2 actively recruiting trials

Pipeline

Phase 1: 1Phase 1/2: 1

Top Sponsors

  • Beijing Biotech2

Indications

  • Cancer2
  • Advanced/Metastatic NSCLC1
  • Recurrent High Grade Glioma1
  • Recurrent Glioblastoma1
  • Malignant Glioma1

Other2 trials

Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC
Phase 1/2
Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma
Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.